People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

anxiety, vomiting, feeling drunk, increased blood pressure, and sedation. No new safety signals were identified in the trial. Spravato is classified as a Schedule III controlled substance and is ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

anxiety, vomiting, feeling drunk, increased blood pressure, and sedation. No new safety signals were identified in the trial. Spravato is also indicated for the treatment of depressive symptoms in ...

The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...

Common AEs include temporary increased blood pressure; issues with thinking clearly; bladder problems; nausea; dizziness; drowsiness; numbness; anxiety; lack of energy; headache; increased feelings of ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat. The United States Food and Drug Administration (FDA ...

Spravato has a list of potential side effects, including disassociation, dizziness, nausea, sedation, vertigo, decreased feeling or sensitivity, anxiety, lethargy, increased blood pressure ...